Ionis' TTR amyloidosis candidate under Priority Review

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said FDA accepted and granted Priority Review to an NDA for inotersen (IONIS-TTRRx) to treat hereditary transthyretin (TTR) amyloidosis (hATTR). Its PDUFA date is July 6.

An MAA for the transthyretin (TTR) antisense inhibitor is under review in the EU, where it has been granted accelerated assessment...